Dr. Kemaladewi has extensive training in human genetics and development of genetic therapy, with a focus on neuromuscular disorders. She is interested in understanding the molecular mechanisms underlying layers of pathophysiology involved in muscular dystrophies, including muscle atrophy, -regeneration, -fibrosis, and nerve damages. In parallel, the exposure to technology-driven field of human genetics has provided a strong basis on her translational research arm. She has a robust portfolio on the development and evaluation of therapeutic genetics, such as antisense oligonucleotides and CRISPR/Cas to correct mutations and modulate disease modifier genes in mouse models.
